Angle logo

AGL - Angle Share Price

61.5p -0.7  -1.1%

Last Trade - 05/12/19

Sector
Healthcare
Size
Small Cap
Market Cap £107.5m
Enterprise Value £96.4m
Revenue £678k
Position in Universe 954th / 1841
Bullish
Bearish
Unlock AGL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AGL Revenue Unlock AGL Revenue

Net Income

AGL Net Income Unlock AGL Revenue

Normalised EPS

AGL Normalised EPS Unlock AGL Revenue

PE Ratio Range

AGL PE Ratio Range Unlock AGL Revenue

Dividend Yield Range

AGL Dividend Yield Range Unlock AGL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AGL EPS Forecasts Unlock AGL Revenue
Profile Summary

ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.

Directors
Last Annual April 30th, 2019
Last Interim April 30th, 2019
Incorporated December 4, 2003
Public Since March 17, 2004
No. of Shareholders: n/a
No. of Employees: 62
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 172,754,816
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AGL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AGL
Upcoming Events for AGL
Wednesday 29th January, 2020 Estimate
Half Year 2020 Angle PLC Earnings Release
Similar to AGL
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.